VivoSeq
Immunology

Bullous Pemphigoid

34

Pipeline Programs↗

1

Active Trials↗

19

Companies Involved↗

Bullous Pemphigoid is a moderately active landscape with 34 programs across 19 companies. The most active players are Sun Pharmaceutical Industries, Inc., Nihon Pharmaceutical Co., Ltd, TWi Biotechnology, Inc.. 5 therapies are approved with 9 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

6/100

Mech. Concentration

19/100

Completion Rate

70/100

Attrition Rate

24/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sun Pharmaceutical Industries, Inc. logo

Sun Pharmaceutical Industries, Inc.

1 program

Phase 1N

Nihon Pharmaceutical Co., Ltd

1 program

Phase 2T

TWi Biotechnology, Inc.

1 program

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2A

ANS Pharma

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

68%

Small molecule

23 of 34 classified programs — the dominant modality here.

32%ALL OTHERSMonoclonal antibody1132%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 38 pipeline programs.

Analysis

Trial Status

34

clinical trials

Completed19 · 56%
Terminated6 · 18%
Unknown status5 · 15%
Withdrawn2 · 6%
Approved for marketing1 · 3%
Not yet recruiting1 · 3%

Clinical Trials

Trial Activity

34 trials

Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid
Not yet recruiting·CChengdu Kangnuoxing Biopharma,Inc.·Phase 3·NCT07210554·200 enrolled
Efficacy and Safety of Dupilumab in Patients With Bullous Pemphigoid
Completed·PPeking University First Hospital·N/A·NCT05649579·146 enrolled
Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody
Completed·—·Phase 2·NCT04563923·15 enrolled
Efficacy and Safety of Omalizumab in Bullous Pemphigoid
Completed·UUniversity of Iowa·Phase 4·NCT00472030·2 enrolled
Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid
Completed·UUniversity Hospital, Montpellier·Phase 3·NCT02313870·322 enrolled
Observational Study Assessing Outcomes, Treatment Patterns and Related Costs in Patients in Bullous Pemphigoid
Completed·CCHU de Reims·N/A·NCT02837965·149 enrolled
Anti-IL-5 Therapy in Bullous Pemphigoid (BP)
Completed·IInsel Gruppe AG, University Hospital Bern·Phase 2·NCT01705795·32 enrolled
A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
Completed·Regeneron logoRegeneron·Phase 2/3·NCT04206553·106 enrolled
Efficacy and Safety of Ustekinumab in Bullous Pemphigoid
Completed·CCHU de Reims·Phase 2·NCT04117932·18 enrolled
Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid
Completed·UUniversity Hospital, Rouen·Phase 3·NCT00525616·18 enrolled
JAK Inhibitors' Efficacy in Bullous Pemphigoid
Completed·—·N/A·NCT06561256·120 enrolled
Azathioprine or Mycophenolate Mofetil for Bullous Pemphigoid
Completed·UUniversity Hospital Muenster·Phase 2·NCT00431119·70 enrolled
rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects
Completed·AAKARI Therapeutics·Phase 2·NCT04035733·9 enrolled
Evaluation of Safety, Efficacy and Pharmacodynamic Effect of Bertilimumab in Patients With Bullous Pemphigoid
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT02226146·11 enrolled
Efficacy and Safety of add-on Dapsone Versus add-on Methotrexate in Patients With Bullous Pemphigoid
Completed·—·Phase 4·NCT05984381·62 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)